Combined glyburide and insulin therapy in type II diabetes

A. Reich, C. Abraira, A. M. Lawrence

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses. A placebo-controlled, double-blinded design tested the effects of combined glyburide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone. Insulin requirements significantly decreased in both groups during the initial hospitalization when drug or placebo was added, presumably because of enformed dietary compliance. Thereafter, post-prandial glucoses worsened in the placebo group, as did hemoglobin A1(c); neither of these parameters changed on the glyburide group by week 16, except for modest reduction of the 2 h post-lunch glucose. Thus, while combined therapy provides little advantage beyond what can be accomplished with effective doses of intermediate insulin alone, it did reduce the need for this exogenous insulin.

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalDiabetes Research
Volume6
Issue number2
StatePublished - Dec 1 1987

Fingerprint

Glyburide
Type 2 Diabetes Mellitus
Insulin
Glucose
Placebos
Meals
Therapeutics
Lunch
Fasting
Hemoglobins
Hospitalization
Diet
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Reich, A., Abraira, C., & Lawrence, A. M. (1987). Combined glyburide and insulin therapy in type II diabetes. Diabetes Research, 6(2), 99-104.

Combined glyburide and insulin therapy in type II diabetes. / Reich, A.; Abraira, C.; Lawrence, A. M.

In: Diabetes Research, Vol. 6, No. 2, 01.12.1987, p. 99-104.

Research output: Contribution to journalArticle

Reich, A, Abraira, C & Lawrence, AM 1987, 'Combined glyburide and insulin therapy in type II diabetes', Diabetes Research, vol. 6, no. 2, pp. 99-104.
Reich A, Abraira C, Lawrence AM. Combined glyburide and insulin therapy in type II diabetes. Diabetes Research. 1987 Dec 1;6(2):99-104.
Reich, A. ; Abraira, C. ; Lawrence, A. M. / Combined glyburide and insulin therapy in type II diabetes. In: Diabetes Research. 1987 ; Vol. 6, No. 2. pp. 99-104.
@article{9d9ac426067847c3848d6e83a5378063,
title = "Combined glyburide and insulin therapy in type II diabetes",
abstract = "Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses. A placebo-controlled, double-blinded design tested the effects of combined glyburide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone. Insulin requirements significantly decreased in both groups during the initial hospitalization when drug or placebo was added, presumably because of enformed dietary compliance. Thereafter, post-prandial glucoses worsened in the placebo group, as did hemoglobin A1(c); neither of these parameters changed on the glyburide group by week 16, except for modest reduction of the 2 h post-lunch glucose. Thus, while combined therapy provides little advantage beyond what can be accomplished with effective doses of intermediate insulin alone, it did reduce the need for this exogenous insulin.",
author = "A. Reich and C. Abraira and Lawrence, {A. M.}",
year = "1987",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "99--104",
journal = "Diabetes research (Edinburgh, Lothian)",
issn = "0265-5985",
number = "2",

}

TY - JOUR

T1 - Combined glyburide and insulin therapy in type II diabetes

AU - Reich, A.

AU - Abraira, C.

AU - Lawrence, A. M.

PY - 1987/12/1

Y1 - 1987/12/1

N2 - Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses. A placebo-controlled, double-blinded design tested the effects of combined glyburide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone. Insulin requirements significantly decreased in both groups during the initial hospitalization when drug or placebo was added, presumably because of enformed dietary compliance. Thereafter, post-prandial glucoses worsened in the placebo group, as did hemoglobin A1(c); neither of these parameters changed on the glyburide group by week 16, except for modest reduction of the 2 h post-lunch glucose. Thus, while combined therapy provides little advantage beyond what can be accomplished with effective doses of intermediate insulin alone, it did reduce the need for this exogenous insulin.

AB - Present treatment of type II diabetes mellitus often fails to normalize post-prandial glucoses. A placebo-controlled, double-blinded design tested the effects of combined glyburide-insulin therapy over 4 months in 20 patients after achieving good control of fasting glucose with diet and intermediate insulin alone. Insulin requirements significantly decreased in both groups during the initial hospitalization when drug or placebo was added, presumably because of enformed dietary compliance. Thereafter, post-prandial glucoses worsened in the placebo group, as did hemoglobin A1(c); neither of these parameters changed on the glyburide group by week 16, except for modest reduction of the 2 h post-lunch glucose. Thus, while combined therapy provides little advantage beyond what can be accomplished with effective doses of intermediate insulin alone, it did reduce the need for this exogenous insulin.

UR - http://www.scopus.com/inward/record.url?scp=0023620123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023620123&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 99

EP - 104

JO - Diabetes research (Edinburgh, Lothian)

JF - Diabetes research (Edinburgh, Lothian)

SN - 0265-5985

IS - 2

ER -